Sun Pharma Advanced Research Company (SPARC) reported a consolidated net loss of Rs 51.8 crore for the quarter ended June 30, 2025 (Q1 FY26), significantly narrowing from the loss of Rs 95.9 crore in Q1 FY25. However, the company remained in the red for the quarter.
Total income for Q1 FY26 stood at Rs 18.78 crore, down 42.6% from Rs 31.37 crore reported in the same quarter last year. Revenue from operations dropped to Rs 9.64 crore from Rs 16.81 crore year-on-year, reflecting a continued decline in licensing income and product revenues.
Expenses for the quarter came in at Rs 70.59 crore, down from Rs 113.87 crore in Q1 FY25. The reduction in employee costs and clinical trial expenditure contributed to the lower overall expense base.
Despite cost optimization, the company posted a pre-tax loss of Rs 51.8 crore compared to Rs 95.5 crore loss a year earlier. Tax expense for the quarter stood at Rs 6 lakh.
SPARC continues to invest in R&D and drug development, which significantly contributes to its expense structure and quarterly volatility.
Disclaimer: The information provided is for informational purposes only and should not be considered financial or investment advice. Stock market investments are subject to market risks. Always conduct your own research or consult a financial advisor before making investment decisions. Author or Business Upturn is not liable for any losses arising from the use of this information.
